WideCells Group, which is innovating the growing stem cells industry through the delivery of a stem cell insurance plan, has appointed the Co-Founder of Denplan, Dr. Marilyn Orcharton, as Non-Executive Director to its Board.
The company is in the process of rolling out the world's first stem cell insurance plan.
WideCells Group said with experience spanning over five decades and expertise in the healthcare plan development space, Dr. Orcharton is "well-placed to lend her significant expertise" to the Company's leadership team as it continues to develop its stem cell oriented service offering.
The firm the recently launched CellPlan division, delivering the world's first healthcare plan for the global stem cell industry.
Joao Andrade, CEO of WideCells said, "We are extremely pleased to welcome Marilyn to the WideCells team. Having recently launched the world's first global stem cell healthcare programme, we believe that WideCells is on the cusp of revolutionising an exciting market.
"Given her role in establishing Denplan, Marilyn has unparalleled experience of creating very successful healthcare plans, which generate millions of pounds in revenue and we are therefore confident that she will make a great addition to an already strong team of industry professionals.
"We remain excited about the next stages of our development as we focus on leveraging our position as the stem cell industry's first end-to-end services provider, focused on making treatment of this kind accessible and affordable for families worldwide."
